Unknown PHASE2 INTERVENTIONAL NCT00089700

TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 With Optimized Background Therapy in Treatment-Experienced Subjects Infected With HIV-1

Sponsor: Tanox

Conditions HIV Infections

Interventions TNX-355

Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HIV Infections and is currently ongoing. Tanox leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanox

Data source: Tanox

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altamonte Springs, United States , Baltimore, United States , Bradenton, United States , Cincinnati, United States , Houston, United States , Los Angeles, United States , Miami, United States , New Orleans, United States , Phoenix, United States , San Juan, Puerto Rico and 3 more locations